Page 1 | Search Results | Blood | American Society of Hematology

1-9 of 9

Sort by

Sort Order Select

Journal Articles

International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data

Daniel A. Arber, Attilio Orazi, Robert P. Hasserjian, Michael J. Borowitz, Katherine R. Calvo, Hans-Michael Kvasnicka, Sa A. Wang, Adam Bagg, Tiziano Barbui, Susan Branford, Carlos E. Bueso-Ramos, Jorge E. Cortes, Paola Dal Cin, Courtney D. DiNardo, Hervé Dombret, Eric J. Duncavage, Benjamin L. Ebert, Elihu H. Estey, Fabio Facchetti, Kathryn Foucar, Naseema Gangat, Umberto Gianelli, Lucy A. Godley, Nicola Gökbuget, Jason Gotlib, Eva Hellström-Lindberg, Gabriela S. Hobbs, Ronald Hoffman, Elias J. Jabbour, Jean-Jacques Kiladjian, Richard A. Larson, Michelle M. Le Beau, Mignon L.-C. Loh, Bob Löwenberg, Elizabeth Macintyre, Luca Malcovati, Charles G. Mullighan, Charlotte Niemeyer, Olatoyosi M. Odenike, Seishi Ogawa, Alberto Orfao, Elli Papaemmanuil, Francesco Passamonti, Kimmo Porkka, Ching-Hon Pui, Jerald P. Radich, Andreas Reiter, Maria Rozman, Martina Rudelius, Michael R. Savona, Charles A. Schiffer, Annette Schmitt-Graeff, Akiko Shimamura, Jorge Sierra, Wendy A. Stock, Richard M. Stone, Martin S. Tallman, Jürgen Thiele, Hwei-Fang Tien, Alexandar Tzankov, Alessandro M. Vannucchi, Paresh Vyas, Andrew H. Wei, Olga K. Weinberg, Agnieszka Wierzbowska, Mario Cazzola, Hartmut Döhner, Ayalew Tefferi

Blood (2022) 140 (11): 1200–1228.

https://doi.org/10.1182/blood.2022015850

Published: 2022

Includes: Supplemental data

Journal Articles

Phase II Trial of Low Dose, Subcutaneous Decitabine in Myelofibrosis

Olatoyosi M Odenike, John E. Godwin, Koen Van Besien, Dezheng Huo, Dorie Sher, Patrick Burke, Scott E. Smith, Margaret Green, Julia Melnick, James L Wade, Eric P. Lester, Rebecca B. Klisovic, Maria R. Baer, Richard A Larson, Wendy Stock

Blood (2008) 112 (11): 2809.

https://doi.org/10.1182/blood.V112.11.2809.2809

Published: 2008

Journal Articles

New Cytogenetic Abnormalities Are Frequent in AML and MDS Relapsing after Allogeneic Hematopoietic Cell Transplantation (HCT).

Daniel A. Pollyea, MD, Andrew S. Artz, MD, Wendy Stock, MD, Christopher Daugherty, MD, Lucy Godley, MD PhD, Olatoyosi M. Odenike, MD, Elizabeth Rich, MD PhD, Sonali M. Smith, MD, Todd Zimmerman, MD, Yanming Zhang, PhD, Dezheng Huo, PhD, Richard Larson, MD, Koen Van Besien, MD

Blood (2006) 108 (11): 3675.

https://doi.org/10.1182/blood.V108.11.3675.3675

Published: 2006

Journal Articles

The Histone Deacetylase Inhibitor (HDI) Depsipeptide Has Differential Activity in Core Binding Factor AML.

Olatoyosi M. Odenike, Serhan Alkan, Dorie Sher, John E. Godwin, Dezheng Huo, Stephen J. Brandt, Jingping Xie, Yanming Zhang, David H. Vesole, Richard A. Larson, Wendy Stock

Blood (2006) 108 (11): 1956.

https://doi.org/10.1182/blood.V108.11.1956.1956

Published: 2006

Journal Articles

Phase II Study of Decitabine in Myelofibrosis with Myeloid Metaplasia.

Olatoyosi M. Odenike, John E. Godwin, Koen van Besien, Dezheng Huo, Patrick J. Stiff, Dorie Sher, Nicole Klekowski, Margaret Green, Richard A. Larson, Wendy Stock

Blood (2006) 108 (11): 4923.

https://doi.org/10.1182/blood.V108.11.4923.4923

Published: 2006

Journal Articles

Leukemic Relapse after Allogeneic Stem Cell Transplantation with a T-Cell Depleted Reduced Intensity Conditioning (RIST) Regimen.

Daniel A. Pollyea, MD, Andrew S. Artz, MD, Wendy Stock, MD, Lucy Godley, MD, PhD, Olatoyosi M. Odenike, MD, Elizabeth Rich, MD, PhD, Sonali M. Smith, MD, Richard Larson, MD, Koen Van Besien, MD

Blood (2005) 106 (11): 2022.

https://doi.org/10.1182/blood.V106.11.2022.2022

Published: 2005

Journal Articles

The Histone Deacetylase Inhibitor Depsipeptide Has Differential Activity in Specific Cytogenetic Subsets of Acute Myeloid Leukemia (AML).

Olatoyosi M. Odenike, Serhan Alkan, Dorie Sher, John E. Godwin, Dezheng Huo, Matthew Myers, Stephen J. Brandt, Yanming Zhang, David H. Vesole, Richard A. Larson, Wendy Stock

Blood (2004) 104 (11): 264.

https://doi.org/10.1182/blood.V104.11.264.264

Published: 2004

Journal Articles

Clinical Predictors of Transplant Related Mortality after Reduced Intensity Allogeneic Stem Cell Transplantation (RIST).

Daniel A. Pollyea, MD, Andrew S. Artz, MD, MS, Wendy Stock, MD, Sonali M. Smith, MD, Christopher Daugherty, MD, Lucy Godley, MD, PhD, Todd Zimmerman, MD, Olatoyosi M. Odenike, MD, Michael Thirman, MD, Elizabeth Rich, MD, PhD, Richard Larson, MD, Koen Van Besien, MD

Blood (2004) 104 (11): 1145.

https://doi.org/10.1182/blood.V104.11.1145.1145

Published: 2004

Journal Articles

Sequential Phase II Studies of Flavopiridol by 72-Hour Continuous Infusion and 1-Hour Intravenous Bolus for the Treatment of Relapsed B-Cell Chronic Lymphocytic Leukemia: Results from CALGB Study 19805.

John C. Byrd, MD, Bercedis L. Peterson, PhD, Janice L. Gabrilove, MD, Olatoyosi M. Odenike, MD, Michael R. Grever, MD, Kanti R. Rai, MD, James W. Vardiman, MD, Richard A. Larson, MD, Cancer and Leukemia Group B

Blood (2004) 104 (11): 3485.

https://doi.org/10.1182/blood.V104.11.3485.3485

Published: 2004

NARROW

International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data

Phase II Trial of Low Dose, Subcutaneous Decitabine in Myelofibrosis

New Cytogenetic Abnormalities Are Frequent in AML and MDS Relapsing after Allogeneic Hematopoietic Cell Transplantation (HCT).

The Histone Deacetylase Inhibitor (HDI) Depsipeptide Has Differential Activity in Core Binding Factor AML.

Phase II Study of Decitabine in Myelofibrosis with Myeloid Metaplasia.

Leukemic Relapse after Allogeneic Stem Cell Transplantation with a T-Cell Depleted Reduced Intensity Conditioning (RIST) Regimen.

The Histone Deacetylase Inhibitor Depsipeptide Has Differential Activity in Specific Cytogenetic Subsets of Acute Myeloid Leukemia (AML).

Clinical Predictors of Transplant Related Mortality after Reduced Intensity Allogeneic Stem Cell Transplantation (RIST).

Sequential Phase II Studies of Flavopiridol by 72-Hour Continuous Infusion and 1-Hour Intravenous Bolus for the Treatment of Relapsed B-Cell Chronic Lymphocytic Leukemia: Results from CALGB Study 19805.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only